The METAglut1 study is a prospective study to validate the diagnostic performance of the METAglut1 test in patients clinically compatible with GLUT1 Glucose Deficiency Syndrome (GLUT1-DS) or “DE VIVO Disease”.

It will be conducted in about 40 French centers and plans to include between 2500 and 3000 patients over a period of 30 months.
This study has received the support of the European Commission under the H2020 program.

> Link to the article in Clinical Trials…